Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Big tech earnings have inspired a substantial rise in Nasdaq futures in overnight trading after the Federal Reserve, led by ...

Palo Alto Networks' (PANW) potential acquisition of CyberArk (CYBR) would complement Palo Alto's existing and bolster its ...

Vertiv (NYSE:VRT) has agreed to acquire the Great Lakes Data Racks & Cabinets family of companies for $200 million. Vicebio, ...

An update from BB Biotech ( ($CH:BION) ) is now available. In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in ...

On Thursday, Lazard, Inc. (NYSE:LAZ) reported adjusted earnings per share of $0.52 for the second quarter of 2025, significantly beating analyst forecasts of $0.39. This strong performance was driven ...

Following a recommendation from a panel of CDC advisors, HHS Secretary Robert F. Kennedy Jr. on Wednesday ordered that the ...

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of ...